border=0
border=0
Enter any ticker symbol here to see the live quote & chart tools in action
Ticker:   
border=0 border=0 Benefits: /
  • Your filings are automatically published to your site as they are filed.
  • Investors don't have to leave your site to see filings.


  • Product Description
  • Once a report has been filed with the SEC it will be available on the website.



  • SEC Filings Section 16 Filings Only
     
    NOVADEL PHARMA INC filed this S-1/A on 11/05/2010.
    « Prev Page Outline Printer Friendly Entire FilingNext Page »

    Intellectual property rights of third parties could limit our ability to market our products.

    Our commercial success also significantly depends on our ability to operate without infringing the patents or violating the proprietary rights of others. The USPTO keeps U.S. patent applications confidential while the applications are pending. As a result, we cannot determine which inventions third parties claim in pending patent applications that they have filed. We may need to engage in litigation to defend or enforce our patent and license rights or to determine the scope and validity of the proprietary rights of others. It will be expensive and time consuming to defend and enforce patent claims. Thus, even in those instances in which the outcome is favorable to us, the proceedings can result in the diversion of substantial resources from our other activities. An adverse determination may subject us to significant liabilities or require us to seek licenses that third parties may not grant to us or may only grant at rates that diminish or deplete the profitability of the products to us. An adverse determination could also require us to alter our products or processes or cease altogether any related research and development activities or product sales.

    If we cannot meet requirements under our license agreements, we could lost the rights to our products.

    We depend, in part, on licensing arrangements with third parties to maintain the intellectual property rights to our products under development. These agreements may require us to make payments and/or satisfy performance obligations in order to maintain our rights under these licensing arrangements. All of these agreements last either throughout the life of the patents, or with respect to other licensed technology, for a number of years after the first commercial sale of the relevant product.

    In addition, we are responsible for the cost of filing and prosecuting certain patent applications and maintaining certain issued patents licensed to us. If we do not meet our obligations under our license agreements in a timely manner, we could lose the rights to our proprietary technology.

    In addition, we may be required to obtain licenses to patents or other proprietary rights of third parties in connection with the development and use of our products and technologies. Licenses required under any such patents or proprietary rights might not be made available on terms acceptable to us, if at all.

    We rely on confidentiality agreements that could be breached and may be difficult to enforce.

    Although we believe that we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential information to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be difficult and costly to enforce. Although we seek to obtain these types of agreements from our consultants, advisors and research collaborators, to the extent that they apply or independently develop intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to this type of information. If a dispute arises, a court may determine that the right belongs to a third party, and enforcement of our rights can be costly and unpredictable. In addition, we will rely on trade secrets and proprietary know-how that we will seek to protect in part by confidentiality agreements with our employees, consultants, advisors or others. Despite the protective measures we employ, we still face the risk that:

     

     

     

     

    they will breach these agreements;

     

     

     

     

    any agreements we obtain will not provide adequate remedies for this type of breach or that our trade secrets or proprietary know-how will otherwise become known or competitors will independently develop similar technology; and

     

     

     

     

    our competitors will independently discover our proprietary information and trade secrets.

    18






    border=0
    Quote & Chart Package
    Basic Stock Chart
    Basic Stock Quote
    Embedded Quote / Chart
    Embedded Full Quote / Chart
    Interactive Chart
    Intraday Chart
    Pop Up Quote
    Scrolling Ticker

    You are viewing our Quote and Chart Demo using ticker symbol NVDL
    border=0

    T 800.650.1211     F 888.329.6696     E info@stockgroup.com   © 2004 Stockgroup Media Inc.    Disclaimer